Prior Events

LES USA-Canada "Doing Life Sciences Deals in 2024 - Licensing, M&A, and More"

Panels include Structuring Your Life Sciences Transaction - Licensing vs. M&A vs. Asset Sale and Key Issues for Your Biopharma Licensing Deal - IP, Scientific, and More

Learning Outcomes:

  • Deal trends
  • Considerations when structuring your deal
  • Should you do an M&A vs. license vs. asset sale – considerations for deal
  • Strategies for doing a deal with big pharma
  • What does big pharma look for in a deal structure?
  • Is licensing a way to an M&A deal with big pharma?
  • Key non-economic issues for your biopharma licensing deal
  • IP – how does big pharma diligence it, and how can a biotech satisfy a big pharma
  • Scientific rigor – How does a big pharma evaluate your science?
  • How do these key issues play into your license agreement?
  • How do you run an efficient and productive diligence process?
  • How should you time your licensing deal with your data readout?

Read more & register!

Linked InTwitter